Objective To explore the relationship between dyslipidemia and cardiovascular disease risk in 340 patients with diabetes mellitus (DM). Methods A retrospective analysis was conducted on the clinical data of 340 DM patients who visited the West China Hospital of Sichuan University from January 2020 to January 2024 and were followed up for at least one year. According to the occurrence of cardiovascular disease in DM patients within 1 year of follow-up after treatment, the patients were divided into occurrence group and non-occurrence group. The demographic and related disease indicators in the two groups were statistically analyzed, and univariate analysis was performed. Binary logistic regression analysis was used to analyze the independent risk factors affecting the risk of cardiovascular disease in DM patients. Results The survey results showed that 38 out of 340 DM patients developed cardiovascular disease within 1 year of follow-up after treatment, accounting for 11.18%, and 302 cases did not develop cardiovascular disease, accounting for 88.82%. There were no statistical differences in gender, age, education level, family history of DM, smoking history and alcohol drinking history between the two groups (P>0.05). The proportions of DM course (>10 years), hypertension history and abnormal blood lipid-related indicators in the occurrence group were higher than those in the non-occurrence group (P<0.05). Binary logistics regression analysis showed that DM course>10 years, history of hypertension and abnormal blood lipid-related indicators were independent risk factors affecting the risk of cardiovascular disease in DM patients (P<0.05). Conclusion The course of DM, history of hypertension, and abnormal blood lipid-related indicators in DM patients significantly increase the risk of cardiovascular disease. It is necessary to actively monitor and manage blood lipid levels to reduce the risk of cardiovascular disease.

Objective To understand the occurrence of hepatic dysfunction induced by imipenem-cilastatin sodium in preadult inpatients and analyze the influencing factors. Methods Data of inpatients receiving imipenem-cilastatin sodium treatment in Xiangya Hospital of Central South University from January 1st,2016 to December 31st,2016 were collected and analyzed retrospectively. The patients′ general condition,utilization of imipenem-cilastatin sodium,combined medication,clinical effect,and liver function etc. were recorded. The influencing factors of hepatic dysfunction,especially severe liver injury caused by imipenem-cilastatin sodium were analyzed. Results A total of 143 preadult inpatients were enrolled into this study. Of them,86 patients were males and 57 were females;61 of them were <1 year old,9 were 1-3 years old,6 were 4-10 years old,67 of them were 11-18 years old,and their median age was 9 years. There were 176 infections in the 143 patients. Most of the infections were respiratory tract infection,sepsis, and septicemia. Imipenem-cilastatin sodium was given via intravenous infusion in all patients. At the same daily dosage,the drug was given every 6 hours in 30 patients(21.0%),every 8 hours in 79 patients (55.2%),every 12 hours in 31 patients(21.7%),once daily in 3 patients(2.1%). Eighty-five patients were given combined drugs that could cause liver dysfunction,such as vancomycin,voriconazole, fluconazole,and azithromycin etc. Of the 143 patients,59 had hepatic dysfunction(41.3%),24 had liver injury(16.8%),and 11 had severe liver injury(7.7%). Thirty-four patients with hepatic dysfunction received drugs that could cause liver dysfunction during the imipenem-cilastatin sodium treatment. Occurrence of liver dysfunction was not correlated with any of the following factors:patients′ gender,ages, whether or not having malignant tumor,systemic infections,frequency of administration at the same daily dosage,combination drugs that could cause liver dysfunction,liver-protective drugs use before imipenem-cilastatin sodium treatment(all P>0.05). However,the difference in the incidence of severe liver injury between the <1 year old and 11-18 years old patients was statistically significant[18.0%(11/61)vs. 0(0/67),P<0.001],the difference in the incidence of severe liver injury between the inpatients with malignancies or not was statistically significant[0(0/46)vs. 11.3%(11/97),P<0.01],the difference in the incidence of severe liver injury between the inpatients whose administration frequency was every 6 hours and once daily was statistically significant[0(0/30)vs. 1/3,P=0.001]. Conclusions Non-adult inpatients who were treated with imipenem-cilastatin sodium were prone to develop hepatic dysfunction. Inpatients at age <1 year or receiving higher single dose are more likely to have severe liver injury.

Objective To understand the occurrence of hepatic dysfunction induced by imipenem-cilastatin sodium in preadult inpatients and analyze the influencing factors. Methods Data of inpatients receiving imipenem-cilastatin sodium treatment in Xiangya Hospital of Central South University from January 1st,2016 to December 31st,2016 were collected and analyzed retrospectively. The patients′ general condition,utilization of imipenem-cilastatin sodium,combined medication,clinical effect,and liver function etc. were recorded. The influencing factors of hepatic dysfunction,especially severe liver injury caused by imipenem-cilastatin sodium were analyzed. Results A total of 143 preadult inpatients were enrolled into this study. Of them,86 patients were males and 57 were females;61 of them were <1 year old,9 were 1-3 years old,6 were 4-10 years old,67 of them were 11-18 years old,and their median age was 9 years. There were 176 infections in the 143 patients. Most of the infections were respiratory tract infection,sepsis, and septicemia. Imipenem-cilastatin sodium was given via intravenous infusion in all patients. At the same daily dosage,the drug was given every 6 hours in 30 patients(21.0%),every 8 hours in 79 patients (55.2%),every 12 hours in 31 patients(21.7%),once daily in 3 patients(2.1%). Eighty-five patients were given combined drugs that could cause liver dysfunction,such as vancomycin,voriconazole, fluconazole,and azithromycin etc. Of the 143 patients,59 had hepatic dysfunction(41.3%),24 had liver injury(16.8%),and 11 had severe liver injury(7.7%). Thirty-four patients with hepatic dysfunction received drugs that could cause liver dysfunction during the imipenem-cilastatin sodium treatment. Occurrence of liver dysfunction was not correlated with any of the following factors:patients′ gender,ages, whether or not having malignant tumor,systemic infections,frequency of administration at the same daily dosage,combination drugs that could cause liver dysfunction,liver-protective drugs use before imipenem-cilastatin sodium treatment(all P>0.05). However,the difference in the incidence of severe liver injury between the <1 year old and 11-18 years old patients was statistically significant[18.0%(11/61)vs. 0(0/67),P<0.001],the difference in the incidence of severe liver injury between the inpatients with malignancies or not was statistically significant[0(0/46)vs. 11.3%(11/97),P<0.01],the difference in the incidence of severe liver injury between the inpatients whose administration frequency was every 6 hours and once daily was statistically significant[0(0/30)vs. 1/3,P=0.001]. Conclusions Non-adult inpatients who were treated with imipenem-cilastatin sodium were prone to develop hepatic dysfunction. Inpatients at age <1 year or receiving higher single dose are more likely to have severe liver injury.